AcuCort’s approved drug changes its name to Zeqmelit™
AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the Swedish Medical Product Agency has approved the company’s application to change the brand name of its drug in Sweden, from ISICORT to Zeqmelit™. The same drug was recently approved under the name Zeqmelit™ in Denmark and Norway.
In the development of the drug Zeqmelit™, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions.
The drug is already approved in Denmark and Norway under the name Zeqmelit™. The registration process for selected key markets is underway with a strong focus on registration applications for several countries within the EU. AcuCort’s overarching goal is to commercialize Zeqmelit™ globally, i.e. in the EU, the US and in other priority markets.
“It is gratifying that AcuCort's first approved drug is now approved under one and the same name, Zeqmelit™, throughout Scandinavia. Intensive work is underway with the goal of registration approval in additional markets. During the work process, it has become clear that Zeqmelit™ is the brand name that is best suited for most of our priority markets. I look forward to further approvals of Zeqmelit™ and the upcoming commercialization,” says Jonas Jönmark, CEO of AcuCort.
The information was submitted for publication, through the agency of the contact person below, on October 17, 2022.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit™, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. Zeqmelit™ is approved in Sweden, Denmark and Norway. Altogether, this strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.